These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 7663532)
1. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532 [TBL] [Abstract][Full Text] [Related]
2. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Brøsen K; de Morais SM; Meyer UA; Goldstein JA Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772 [TBL] [Abstract][Full Text] [Related]
3. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668 [TBL] [Abstract][Full Text] [Related]
4. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632 [TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219 [TBL] [Abstract][Full Text] [Related]
6. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Feng HJ; Huang SL; Wang W; Zhou HH Br J Clin Pharmacol; 1998 Jan; 45(1):27-9. PubMed ID: 9489590 [TBL] [Abstract][Full Text] [Related]
7. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148 [TBL] [Abstract][Full Text] [Related]
8. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407 [TBL] [Abstract][Full Text] [Related]
9. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201 [TBL] [Abstract][Full Text] [Related]
10. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Tybring G; Bertilsson L Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124 [TBL] [Abstract][Full Text] [Related]
11. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266 [TBL] [Abstract][Full Text] [Related]
12. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259 [TBL] [Abstract][Full Text] [Related]
14. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. de Morais SM; Wilkinson GR; Blaisdell J; Nakamura K; Meyer UA; Goldstein JA J Biol Chem; 1994 Jun; 269(22):15419-22. PubMed ID: 8195181 [TBL] [Abstract][Full Text] [Related]
15. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Takakubo F; Kuwano A; Kondo I Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668 [TBL] [Abstract][Full Text] [Related]
16. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932 [TBL] [Abstract][Full Text] [Related]
17. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147 [TBL] [Abstract][Full Text] [Related]
18. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. Llerena A; Valdivielso MJ; Benítez J; Bertilsson L Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192 [TBL] [Abstract][Full Text] [Related]
19. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Goldstein JA; Blaisdell J Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779 [No Abstract] [Full Text] [Related]
20. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Kubota T; Chiba K; Ishizaki T Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]